Sun Pharma gets DCGI nod for generic semaglutide injection in India

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

SUNPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.2%Reaction day

₹1635.50

prior close

₹1640.00

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)-1.1%+1.0% vs market

Pharmaceuticals peers, median of 155sector-1.5%+1.4% vs sector

On the reaction day the stock moved 1.0 pts more than Nifty 100 and 1.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.8

10m

-0.4

15m

-0.3

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.2-1.1+1.0-1.5+1.4

Next day

+0.2-0.6+0.8-2.1+2.3

-1.7+0.3-2.0-0.9-0.7

-2.8+0.6-3.4-1.3-1.4

-2.5+0.2-2.6-1.1-1.4

-0.4-0.8+0.4-1.4+1.0

+4.1+2.0+2.1+1.4+2.7

15d

+3.8+1.8+2.1+0.0+3.8

+5.9+1.9+4.0+0.3+5.6

+6.8-10.7+17.5-9.9+16.7

+2.6-3.0+5.6+2.7-0.1

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sun Pharma received DCGI approval to manufacture and market a generic version of semaglutide injection in India for chronic weight management in adults. It will launch under the brand name Noveltreat after the semaglutide patent expires in India. The product, backed by a Phase III trial in India, comes in five dose strengths from 0.25 mg to 2.4 mg, given once weekly via a prefilled pen. This follows the December 2025 DCGI approval for semaglutide for type 2 diabetes under brand Sematrinity.

Likely market impact

Entry into India's fast-growing obesity drug market; actual sales depend on patent expiry timing and pricing competition.